Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces
- 1 August 2000
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (8) , 1711-1721
- https://doi.org/10.1517/13543784.9.8.1711
Abstract
Binding of microbial cell surface adhesins to host receptor molecules is a critical early step in microbial infection and pathogenesis. Anti-adhesive strategies aimed at blocking this interaction offer an attractive means of preventing infection at an early stage. The strategy should reduce the likelihood of resistant strains of microorganisms emerging, since those that do not bind will not be subjected to sustained selective pressure, as may occur with antibiotic therapy. Three classes of adhesion-blocking agent have been investigated, namely anti-adhesin antibodies, adhesin analogues and receptor analogues. The effectiveness of a number of these adhesion-blocking compounds has been demonstrated in human and animal models of infection. Direct application to the tooth surface of anti-adhesin monoclonal antibody, or a synthetic peptide adhesion epitope, prevented infection with the oral pathogen, Streptococcus mutans in humans. Intranasal administration of a soluble receptor analogue significantly reduced virus production and symptoms following experimental infection with rhinovirus. Similarly, all three types of anti-adhesion agent protected against a variety of infections at other mucosal surfaces in animal models. A common finding from these studies is the long duration of protection, which cannot be due to persistence of the anti-adhesion agent, but may be the result of competitive exclusion by members of the normal flora at specific mucosal surfaces. Development of these novel antimicrobial agents is particularly timely in view of the increasing concern over the spread of antibiotic resistance.Keywords
This publication has 29 references indexed in Scilit:
- Protection against Candidiasis by an Immunoglobulin G3 (IgG3) Monoclonal Antibody Specific for the Same Mannotriose as an IgM Protective AntibodyInfection and Immunity, 2000
- Tyrosine phosphorylation of theHelicobacter pyloriCagA antigen aftercag-driven host cell translocationProceedings of the National Academy of Sciences, 2000
- Hope for the post-antibiotic era?Nature Biotechnology, 1999
- Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humansNature Medicine, 1998
- Action against antibiotic resistance: no time to loseThe Lancet, 1998
- Epithelial attachment alters the outcome of Helicobacter pylori infectionProceedings of the National Academy of Sciences, 1998
- Altered adherence in strains ofCandida albicansharbouring null mutations in secreted aspartic proteinase genesFEMS Microbiology Letters, 1998
- Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.Proceedings of the National Academy of Sciences, 1996
- The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract.Proceedings of the National Academy of Sciences, 1994
- Recognition of a bacterial adhesin by an integrin: Macrophage CR3 (αMβ2, ) binds filamentous hemagglutinin of Bordetella pertussisCell, 1990